Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening
Cancer Science · 2026-06 · 117 (6) · 1713-1723
DOI: 10.1111/cas.70390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 13.04.2026. Verfasst von Keiko Taniguchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Naphthoquinones, High-Throughput Screening Assays, gamma-Glutamylcyclotransferase, Enzyme Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
γ‐Glutamylcyclotransferase (GGCT) is a highly expressed protein in various cancers, and its knockdown and inhibitors suppress the growth of cancer cells in vitro and in vivo. Although GGCT is a promising target for anti‐cancer strategies, no drugs have progressed to clinical availability yet. We established a novel target‐based and cell‐based screening method for GGCT inhibitors, enabling the efficient discovery of compounds that inhibit intracellular GGCT activity. Using the chemiluminogenic probe LISA‐103 in response to GGCT enzymatic activity, high‐throughput screening for GGCT inhibitors was performed in lung cancer SW1573 cells. The hit compound plumbagin was identified as a novel GGCT inhibitor that suppressed its activity intracellularly. Plumbagin directly bound to a GGCT‐recombinant protein and inhibited its activity. Moreover, plumbagin up‐regulated p21, a cyclin‐dependent kinase inhibitor, and activated the tumor suppressor RB protein, inhibiting cell growth and cell cycle progression in breast MCF7 and colon HCT116 cancer cell lines. These phenomena induced by plumbagin mimicked the effect of GGCT depletion. The treatment with plumbagin suppressed tumor growth of HCT116 xenograft mice. These results suggest the potential of plumbagin in cancer therapy as a GGCT inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Peptide Institute Inc., Osaka, Japan.
- Laboratory of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan.
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
ORCID-Profile: Keiko Taniguchi, Mano Horinaka, Hiromi Ii, Susumu Nakata, Taku Yoshiya, Toshiyuki Sakai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Taniguchi, K., Nohara, Y., Horinaka, M., Nose, K., Mori, M., Ii, H., Kawakami, H., Yano, K., Nakata, S., Yoshiya, T., & Sakai, T. (2026). Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening. Cancer Science, 117(6), 1713-1723. https://doi.org/10.1111/cas.70390
Vancouver
Taniguchi K, Nohara Y, Horinaka M, Nose K, Mori M, Ii H, et al. Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening. Cancer Science. 2026;117(6):1713-1723. doi:10.1111/cas.70390
BibTeX
@article{Taniguchi2026,
author = {Taniguchi, Keiko and Nohara, Yukie and Horinaka, Mano and Nose, Kozue and Mori, Masaya and Ii, Hiromi and Kawakami, Hiroko and Yano, Kazuto and Nakata, Susumu and Yoshiya, Taku and Sakai, Toshiyuki},
title = {Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {6},
pages = {1713--1723},
doi = {10.1111/cas.70390}
}
EUVIMED